PD-L1 Anticorps
(CD274 (PD-L1))
Choisissez l’un des 458 anticorps PD-L1 de notre liste de produits basés sur 15 publications et 153 images de validation.
Découvrez des anticorps PD-L1 fiables issus d’une large sélection de fabricants renommés. Notre portefeuille permet une détection précise de PD-L1 dans plusieurs espèces, y compris Human, Mouse, Rat, Cow, Non-Human Primate, Pig, Monkey, Cynomolgus, Cat, Dog, Horse, et prend en charge diverses applications de recherche telles que WB, FACS, IHC, ELISA, IF.
Trouvez rapidement l’anticorps adapté grâce à nos outils de recherche, de filtrage et de comparaison. Chaque page produit fournit des données de validation détaillées, des références bibliographiques et des retours d’utilisateurs. Contrairement aux ressources dédiées uniquement à la comparaison, vous pouvez acheter directement les anticorps sur notre site. Choisissez parmi des anticorps polyclonaux, monoclonaux ou recombinants PD-L1, issus de différents hôtes tels que Rabbit, Mouse, Rat. Parcourez nos produits ci-dessous et commandez directement pour soutenir vos recherches en toute confiance.
Les noms alternatifs de PD-L1 sont CD274, Cd274, PDCD1LG2.
Filtrer les résultats:
458 Résultats
PD-L1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Monoclonal
PDL1-4280R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
IHC
Hôte: Lapin
Monoclonal
PDL1-8408R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Monoclonal
A326
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
Hôte: Lapin
Monoclonal
PDL1-7568R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Monoclonal
PDL1-8591R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Souris
FACS
Hôte: Lapin
Monoclonal
YDC 127-1-1
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Monoclonal
PDL1-8591R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain
WB, IHC
Hôte: Lapin
Monoclonal
PDL1-8809R
unconjugated
Recombinant Antibody
PD-L1
Reactivité: Humain, Non-Human Primate
FACS, IHC
Hôte: Souris
Monoclonal
29E-2A3
Biotin
PD-L1
Reactivité: Humain, Souris, Rat
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 350
PD-L1
Reactivité: Humain, Souris, Rat
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 594
PD-L1
Reactivité: Souris
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 594
PD-L1
Reactivité: Humain, Souris, Rat
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 647
PD-L1
Reactivité: Humain, Souris, Rat
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 555
PD-L1
Reactivité: Humain, Souris, Rat
WB, FACS
Hôte: Lapin
Polyclonal
AbBy Fluor® 555
PD-L1
Reactivité: Souris
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 488
PD-L1
Reactivité: Humain, Souris, Rat
WB, FACS
Hôte: Lapin
Polyclonal
AbBy Fluor® 488
PD-L1
Reactivité: Humain, Souris, Rat
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 488
PD-L1
Reactivité: Souris
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 555
PD-L1
Reactivité: Humain, Souris, Rat
WB, FACS
Hôte: Lapin
Polyclonal
AbBy Fluor® 680
Dernières publications pour nos PD-L1 Anticorps
: "Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin." dans: PLoS ONE, Vol. 16, Issue 1, pp. e0245581, (2021) (PubMed).
: "Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma." dans: Frontiers in oncology, Vol. 11, pp. 757919, (2021) (PubMed).
: "Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder." dans: Journal of clinical medicine, Vol. 9, Issue 5, (2020) (PubMed).
: "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer." dans: Nature communications, Vol. 11, Issue 1, pp. 1669, (2020) (PubMed).
: "Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer." dans: PLoS ONE, Vol. 15, Issue 3, pp. e0230449, (2020) (PubMed).
: "MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma." dans: Aging, Vol. 12, Issue 2, pp. 1213-1236, (2020) (PubMed).
: "Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. ..." dans: Cancer immunology research, Vol. 7, Issue 5, pp. 841-852, (2019) (PubMed).
: "Autophagy inhibition enhances PD-L1 expression in gastric cancer." dans: Journal of experimental & clinical cancer research : CR, Vol. 38, Issue 1, pp. 140, (2019) (PubMed).
: "Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy." dans: PLoS ONE, Vol. 14, Issue 5, pp. e0215990, (2019) (PubMed).
: "Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy." dans: Journal of controlled release : official journal of the Controlled Release Society, Vol. 308, pp. 29-43, (2019) (PubMed).
: "Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma." dans: Frontiers in oncology, Vol. 11, pp. 757919, (2021) (PubMed).
: "Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder." dans: Journal of clinical medicine, Vol. 9, Issue 5, (2020) (PubMed).
: "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer." dans: Nature communications, Vol. 11, Issue 1, pp. 1669, (2020) (PubMed).
: "Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer." dans: PLoS ONE, Vol. 15, Issue 3, pp. e0230449, (2020) (PubMed).
: "MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma." dans: Aging, Vol. 12, Issue 2, pp. 1213-1236, (2020) (PubMed).
: "Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway. ..." dans: Cancer immunology research, Vol. 7, Issue 5, pp. 841-852, (2019) (PubMed).
: "Autophagy inhibition enhances PD-L1 expression in gastric cancer." dans: Journal of experimental & clinical cancer research : CR, Vol. 38, Issue 1, pp. 140, (2019) (PubMed).
: "Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy." dans: PLoS ONE, Vol. 14, Issue 5, pp. e0215990, (2019) (PubMed).
: "Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy." dans: Journal of controlled release : official journal of the Controlled Release Society, Vol. 308, pp. 29-43, (2019) (PubMed).
Pseudonymes pour PD-L1 Anticorps
CD274 molecule (CD274) AnticorpsCD274 antigen (Cd274) Anticorps
programmed cell death 1 ligand 2 (PDCD1LG2) Anticorps
CD274 molecule (Cd274) Anticorps
A530045L16Rik Anticorps
B7-H Anticorps
B7H1 Anticorps
B7h1 Anticorps
PD-L1 Anticorps
PDCD1L1 Anticorps
Pdcd1l1 Anticorps
PDCD1LG1 Anticorps
Pdcd1lg1 Anticorps
PDL1 Anticorps
Pdl1 Anticorps
RGD1566211 Anticorps
Avez-vous cherché autre chose?
- PCYT2 Anticorps
- PCYOX1L Anticorps
- PCYOX1 Anticorps
- PCTP Anticorps
- PCSK7 Anticorps
- PCSK6 Anticorps
- PCSK5 Anticorps
- PCSK4 Anticorps
- PCSK2 Anticorps
- PCSK1N Anticorps
- PCSK1 Anticorps
- PCP4 Anticorps
- Pcp2 Anticorps
- PCOTH Anticorps
- PCOLCE2 Anticorps
- PCOLCE Anticorps
- PCNXL2 Anticorps
- PCNT Anticorps
- PCNP Anticorps
- PCMTD1 Anticorps
- PDAP1 Anticorps
- PDCD11 Anticorps
- PDCD2 Anticorps
- PDCD2L Anticorps
- PDCD5 Anticorps
- PDCD6 Anticorps
- PDCD7 Anticorps
- PDCL2 Anticorps
- PDCL3 Anticorps
- PDE10A Anticorps
- PDE11A Anticorps
- PDE12 Anticorps
- PDE1A Anticorps
- PDE1B Anticorps
- PDE1C Anticorps
- PDE2A Anticorps
- PDE3A Anticorps
- PDE3B Anticorps
- PDE4A Anticorps
- PDE4B Anticorps
Vous êtes ici:
